Displaying 3601 - 3620 of 4737
Bureau of Competition Statement Regarding the Announcement that Thoratec Corporation Will Not Proceed with Its Proposed Acquisition of HeartWare International
FTC Challenges Thoratec's Proposed Acquisition of HeartWare International
FTC Challenges Carilions Acquisition of Outpatient Medical Clinics
FTC Testifies on Importance of Competition and Antitrust Enforcement to Lower-Cost, Higher-Quality Health Care
Commission Approves FY 2008 HSR Premerger Notification Report; FTC Approves Final Consent Order in Matter Concerning Alta Bates Medical Group
Alta Bates Medical Group, Inc.
Alta Bates Medical Group, Inc., a 600-physician independent practice association serving the Berkeley and Oakland, California, area, settleed Commission charges that it violated federal antitrust law by fixing prices charged to health care insurers. The consent order prohibits Alta Bates from collectively negotiating fee-for-service reimbursements and engaging in related anticompetitive conduct. In addition to price-fixing of fee-for-service reimbursements, the FTC’s complaint alleges an unlawful concerted refusal to deal.
FTC Adds Requirements to 2004 Order to Restore Competition in Process Simulation Software Market
FTC Issues Interim Report on "Authorized Generic" Drugs
Liberty Media Corporation and John C. Malone, United States of America (for the Federal Trade Commission)
John C. Malone, CEO and Chairman of Discovery Holding Company, agreed to pay a $1.4 million civil penalty to settle Federal Trade Commission charges that he violated the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with acquisitions of Discovery shares in 2005 and 2008. The FTC alleged that Malone failed to file the required notice in 2005 after buying Discovery shares, and then in 2008 purchased additional Discovery shares before the expiration of a waiting period required by the HSR Act.
FTC Obtains $1.4 Million Civil Penalty for Premerger Filing Violations
FTC Chairman Leibowitz: Eliminating Pay-for-Delay Pharmaceutical Settlements Would Save Consumers $3.5 Billion Annually
CSL Limited, a corporation, and Cerberus-Plasma Holdings, LLC, In the Matter of
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. Following the FTC's lawsuit to block the transaction, CSL Limited announced that it would not proceed with its proposed acquisition.
FTC Testifies on "Competition Issues and Follow-on Biologic Drugs"
FTC Releases Report on Follow-on Biologic Drug Competition
Statement of the FTC's Bureau of Competition Regarding the Announcement that CSL Will Not Proceed with its Proposed Acquisition of Talecris Biotherapeutics
Commission Grants, in Part, Petition of Hexion LLC and Huntsman Corporation to Reopen and Set Aside Orders
Chairman, Commissioners Issue Statement on Endocare, Inc.s Announcement That it has Terminated its Merger Agreement with Galil Medical Ltd.
Displaying 3601 - 3620 of 4737